Clinical trial · Observational
Circulating Biomarkers in Patients With Anal Cancer Treated With Induction Chemotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate the prognostic and predictive value of plasma HPV (pHPV) prior, during and after induction chemotherapy (ICT) in locally advanced squamous cell carcinoma of the anus (SCCA) or synchronous metastatic SCCA patients treated with ICT prior to definitive (chemo)radiotherapy ((C)RT) according to multidisciplinary team (MDT) conferences based decisions. Further to investigate the use of pHPV measurements and other relevant markers for prediction of response and survival after ICT prior to definitive (C)RT.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anal Cancer | Malignant Anal Neoplasm | CURATED_EXACT | 0.92 |
| Circulating Tumor Cell | — | UNRESOLVED | — |
| Human Papilloma Virus | — | UNRESOLVED | — |
| Locally Advanced Squamous Cell Carcinoma | Squamous Cell Carcinoma | CURATED_BROADER | 0.78 |
| Oligometastatic Disease | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Locally advanced or synchronous metastatic anal cancer treated with induction chemotherapy
- description
- Patients with newly diagnosed anal cancer who by standard of care are eligible for induction chemotherapy prior to definitive CRT or radiotherapy alone (RT) will be screened according to inclusion- and exclusion criteria. Patients eligible for induction chemotherapy will be patients with locally advanced or synchronous metastatic anal cancer.
Primary outcomes (1)
- measure
- Overall survival according to circulating tumour DNA status
- timeFrame
- 2 year
- description
- Overall survival: Time from diagnosis to time of dead or date of last follow-up.
Secondary outcomes (3)
- measure
- Disease-free survival according to circulating tumour DNA and immune markers.
- timeFrame
- 2 year
- description
- Time from end of treatment to progression, recurrence or death whatever comes first.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological verified squamous cell carcinoma of the anus * Treatment with ICT prior to definitive CRT or RT due to locally advanced disease or * Patients with synchronous metastatic disease treated with ICT with the purpose of definitive CRT (potentially in combination with organ directed therapy (surgery, RFA, SBRT) for the metastatic sites) * Age ≥ 18 years * Written and orally informed consent Exclusion Criteria: * Contraindications for blood sampling * Other malignancy within the past five years, with exception of basal cell carcinoma
References
Publications (0)
Data not yet available